Printer-friendly versionMr. Listwin is the Chairman of the GenoLogics board and founder and chairman of Canary Foundation, the United States’ only non-profit organization devoted exclusively to early detection of cancer. A 25-year veteran of the technology industry - he was CEO of Openwave and had been the #2 executive at Cisco Systems – Mr. Listwin walked away from his high profile technology career and launched Canary Foundation as a way to address the imbalance in cancer research. Canary Foundation has assembled a science team that includes some of the world's leading cancer researchers to attack early detection in a new, collaborative approach. Canary Foundation's ultimate goal is to speed development of biomarkers that can detect the presence of cancers at their very earliest stage, when they are most treatable and chances for full recovery are greatest. Mr. Listwin also serves on the boards of Sana Security, Stratos Biosciences, and the Listwin Family Foundation. He is also a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center. A native of Canada, Mr. Listwin holds a B.S. in electrical engineering and an honorary doctorate of law from the University of Saskatchewan.
Michael Ball, the CEO for GenoLogics Life Sciences Software, has 20 years of experience in sales, marketing and business development with high growth technology companies. Michael has held VP positions at various technology companies including five years in executive management with Creo Products Inc. as VP Business Development and VP European Sales and Service. In addition, Michael was VP at Carmanah Technologies, spent seven years at Digital Equipment Corp. and has experience with several technology start-ups. Michael has a sound knowledge of mergers, acquisitions and strategic partnerships, extensive international experience and has been instrumental in repositioning GenoLogics from a single product company to a comprehensive research informatics vendor for the life sciences industry.
Steve co-founded Yaletown Venture Partners in 2001 and has more than 18 years experience financing and working with entrepreneurial technology teams. Yaletown is a venture capital fund based in Vancouver backed by leading institutional investors in Canada and the United States. Previously, Steve established and built TD Bank’s technology financing business on the west coast of Canada, was a senior executive in the Technology industry group of PricewaterhouseCoopers, and began his career as a software engineer with Accenture concentrating on regulated industry workflow management. Steve is presently active on the boards of Genologics, Mixpo, Cogent Health Solutions, the Canadian Venture Capital Association and is a past director of ActiveState Corp (acquired by Sophos PLC). Steve is on the editorial boards of Private Capital magazine and Business in Vancouver newspaper. He is a graduate of the University of British Columbia and British Columbia Institute of Technology magna cum laude.
Ms. Pacella joined GrowthWorks Capital in April 2001. She previously worked for an investment bank in mergers and acquisitions across a variety of industries including financial services and technology. More recently, Ms. Pacella worked at an interactive media firm assisting the company in operational activities and strategic initiatives. Ms. Pacella has a degree in Business Administration and is a Chartered Financial Analyst. Ms. Pacella also serves on the board of Tap Solutions Inc.
Mr. Waite has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite holds an AB in History from Kenyon College and an MBA from Harvard University. In addition to the GenoLogics board, Mr. Waite currently serves on the boards of: Accelerator, Airgo Networks, Complete Genomics, NanoString, Plectix BioSystems, and SafeHarbor. Mr. Waite is a board member of the NVCA and of the Washington Technology Alliance. He is also a Trustee at Kenyon College and a member of the OHSU (Oregon Health Sciences University) BSIF Advisory Board.
